Key result
High-dose carteolol (10.0 mg/kg twice daily) reduced mortality to 22% compared to 59% in untreated turkey poults with furazolidone-induced dilated cardiomyopathy.
Why the study?
Does carteolol improve survival and reverse cellular remodeling in a turkey model of dilated cardiomyopathy?
Does carteolol improve survival and reverse cellular remodeling in a turkey model of dilated cardiomyopathy?
Absolute Event Rate: 22% vs 59%
High-dose carteolol significantly improved survival and reversed cellular and contractile abnormalities in a turkey model of dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating in avian DCM; requires mammalian validation before any clinical consideration.
Gwathmey et al. (1999) studied Dilated cardiomyopathy (DCM). Carteolol vs. Nontreated DCM group was evaluated on Mortality. High-dose carteolol (10.0 mg/kg twice daily) reduced mortality to 22% compared to 59% in untreated turkey poults with furazolidone-induced dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: